American HealthCare Capital is pleased to introduce a licensed ABA Therapy company in Northeast Texas for sale. The company has been in business since 2016 and has developed a reputation as one of the premier providers of in-home and center-based therapy for autism clients in the region. The company primarily treats children 14 and younger, working with each family to create individualized goals and behavior intervention plans that are specific to each patient’s needs. Additionally, they provide care for adolescents with special needs, including a wide range of learning, social, and emotional disabilities.
The company is in-network with some of the largest providers and has a payer mix of roughly 90% in-network insurance and 10% private pay. Although they were initially impacted by the COVID-19 pandemic, the business quickly recovered because of the company’s ability to adapt to a telehealth model, allowing them to continue seeing clients when in-person treatment was not an option. In 2019, the company generated over $1 million in gross revenues. In 2020, despite the pandemic, they are on track to generate $1.8 million with an adjusted EBITDA of $310,000 (17%). However, in Q3 (July – September), the company experienced a surge in demand and a dramatic rise in revenue and EBITDA, with average monthly revenues of $195,000 and an average monthly EBITDA of $47,400 (24%). Using Q3 results, their projected annual run rate through Q2 2021 is $2.3 million with approximately $600,000 in adjusted EBITDA.
All employees are expected to stay on under new ownership and management is in place to take over the sellers’ responsibilities. The seller is also available to assist during a short transition as needed.
The asking price for this opportunity is $2.5 million.
If you would like to learn more, please use the link on the right-hand side of the page to execute our NDA. You will need to copy the Listing Code (Example: TXMC1A) and Listing Title (Example: $1 Million Home Health Agency in Texas) from the summary above to complete the NDA.